** Shares of drugmaker Eton Pharmaceuticals ETON.O rise 3.5% to $14.90 premarket

** Co says the US FDA has accepted its application for potential approval of its drug candidate ET-600

** If approved, ET-600 is expected to be the only oral liquid option on the market for central diabetes insipidius, ETON says

** Central diabetes insipidius is a condition where the body doesn't produce enough vasopressin, a hormone that regulates water balance by signaling kidneys to conserve water

** The FDA will give its decision on ET-600 on or before February 26, 2026

** Up to last close, stock had risen 8% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))